Comparison
While GHK-Cu acts as a tissue-remodeling and wound-healing signal, enhancing skin regeneration, angiogenesis, and repair while reducing inflammation and oxidative damage in experimental models31383, Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880.
While GHK-Cu works as an endogenous tripeptide, Gly-His-Lys, that chelates Cu²⁺ and modulates gene expression, stimulating collagen, elastin, proteoglycan, and glycosaminoglycan synthesis while exerting antioxidant and anti-inflammatory effects31383, Liraglutide is a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880.
GHK-Cu is 3 amino acids long, whereas Liraglutide is longer as it has a length of 31 amino acids. GHK-Cu is made up of a sequence of Glycine, Histidine, Lysine. Liraglutide is made up of a sequence of sequence data not available in the current dataset.
GHK-Cu
Not assigned in the current dataset.
Liraglutide
GCG